💧 GU Oncology — 2026-W42

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Phase I/II first-in-human study of the PROTAC AR degrader bavdegalutamide in ARPI-pretreated metastatic castration-resistant prostate cancer, published in JCO. Shows activity concentrated in tumors with specific AR mutations, supporting biomarker-selected development of AR degraders.

Single-arm phase 2 trial in transurethrally unresectable ERBB2-positive very high-risk non-muscle-invasive bladder cancer, published in JAMA Oncol. Tests disitamab vedotin plus tislelizumab as a bladder-sparing option for patients ineligible for or declining cystectomy, suggesting promise pending larger confirmatory studies.

Translational narrative review in The Oncologist covering rare prostate cancer histologies (neuroendocrine, ductal, cribriform and others) and their biology. It links histology to actionable alterations and biomarker-selected therapy, helping oncologists think about treatment in these aggressive variants.

Exploratory translational analysis of the phase 2 TALAPRO-1 trial of talazoparib in pretreated metastatic castration-resistant prostate cancer with HRR alterations, published in Eur J Cancer. Links BRCA2 alterations to prolonged benefit and HRR reversions/PARP1 variants to resistance, informing PARP inhibitor patient selection and resistance mechanisms.

Narrative review in Crit Rev Oncol Hematol on tumor microenvironment mechanisms of immune checkpoint inhibitor resistance in prostate cancer and emerging combination strategies. Informs future trial directions but does not change current practice.

Post hoc exploratory subgroup analysis of the phase 3 PROpel RCT in first-line metastatic castration-resistant prostate cancer without BRCA mutations, published in Eur Urol Oncol. Suggests olaparib plus abiraterone retains some progression-free benefit in non-BRCA patients, informing decisions in this group, though overall survival is not clearly improved.

Real-world clinicogenomic database analysis in adults with advanced solid tumors, published in JCO Precision Oncology. Uses matched emulation to assess whether NTRK fusions affect survival independent of TRK inhibitor therapy, informing prognostic interpretation rather than treatment selection.

Post hoc analysis of the STAMPEDE randomized trial with linked health records, published in European Urology, assessing major cardiovascular events with treatment intensification and testing a CV risk score. It informs cardiovascular risk counselling and monitoring during ARPI and other intensified therapy.